AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Related Videos
Related Content

Glaucoma 360: Eyedrop targets and reduces episcleral venous pressure in glaucoma

February 3rd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Foundation Fighting Blindness to host PRPH2 and Associated Retinal Diseases Workshop

January 26th 2023

What to expect from virtual AAO 2020

November 5th 2020

Risk of rhegmatogenous retinal detachment rises following cataract surgery

October 4th 2022

Identifying risk factors for development of rhegmatogenous retinal detachments in fellow eyes

October 3rd 2022

Glaucoma 360: Eyedrop targets and reduces episcleral venous pressure in glaucoma

February 3rd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Foundation Fighting Blindness to host PRPH2 and Associated Retinal Diseases Workshop

January 26th 2023

What to expect from virtual AAO 2020

November 5th 2020

Risk of rhegmatogenous retinal detachment rises following cataract surgery

October 4th 2022

Identifying risk factors for development of rhegmatogenous retinal detachments in fellow eyes

October 3rd 2022

Glaucoma 360: Eyedrop targets and reduces episcleral venous pressure in glaucoma

February 3rd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Foundation Fighting Blindness to host PRPH2 and Associated Retinal Diseases Workshop

January 26th 2023

What to expect from virtual AAO 2020

November 5th 2020

Risk of rhegmatogenous retinal detachment rises following cataract surgery

October 4th 2022

Identifying risk factors for development of rhegmatogenous retinal detachments in fellow eyes

October 3rd 2022
Advertise
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.